Compare DRVN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRVN | ADPT |
|---|---|---|
| Founded | 1972 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2020 | 2019 |
| Metric | DRVN | ADPT |
|---|---|---|
| Price | $12.72 | $13.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $19.00 | $17.78 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 59.82 | ★ 63.89 |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $2,339,588,000.00 | $276,976,000.00 |
| Revenue This Year | N/A | $3.98 |
| Revenue Next Year | $1.53 | $22.72 |
| P/E Ratio | $18.22 | ★ N/A |
| Revenue Growth | 1.54 | ★ 54.77 |
| 52 Week Low | $9.80 | $7.21 |
| 52 Week High | $19.74 | $20.76 |
| Indicator | DRVN | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 44.44 |
| Support Level | $11.71 | $12.22 |
| Resistance Level | $13.54 | $15.38 |
| Average True Range (ATR) | 0.60 | 0.74 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 58.04 | 41.94 |
Driven Brands Holdings Inc is an automotive services company in North America. Its platform provides high-quality services to an extensive range of retail and commercial customers. The company provides an extensive range of core consumer and commercial automotive needs, including paint, collision, glass, and repair services, as well as a variety of high-frequency services, such as oil changes and car washes. The company segments include: Maintenance, Car Wash, Paint, Collision & Glass, and Platform Services. It derives maximum revenue from Maintenance Segment. Geographically, the company operates into United States, Canada and Rest of the World.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.